🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being described as a "major milestone" in the effort against drug-resistant strains of the pathogen, according to health experts.

An International Challenge

The sexually transmitted infection are on the rise worldwide, with data suggesting in excess of 82 million instances annually. Especially elevated rates are seen in the African continent and nations within the WHO's designated area, which encompasses Mongolia and China to New Zealand. Across England, cases have hit a historical peak, while figures across Europe in 2023 were triple the level compared to figures for 2014.

“The authorization of fresh medications for gonorrhoea is an important and timely step in the face of rising global incidence, increasing antimicrobial resistance and the extremely scarce treatment choices presently on offer.”

Medical experts are increasingly worried about the increase in drug-resistant strains. The World Health Organization has designated it as a "priority pathogen". A tracking program revealed that the effectiveness of standard treatments like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Two New Therapies Receive Approval

Zoliflodacin, alternatively called Nuzolvence, was authorized by the US FDA in recent days for treating gonorrhoea. This disease can lead to major issues, including the inability to conceive. Researchers hope that targeted use of this new drug will help delay the emergence of superbugs.

Another new antibiotic, developed by the drugmaker GlaxoSmithKline, was also approved in the same week. This drug, which is additionally indicated for urinary tract infections, was proven in research to be successful in treating superbug versions of the gonorrhoea bacteria.

A Unique Partnership

Zoliflodacin stemmed from a new, not-for-profit approach for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the drug firm Innoviva to see it through.

“This approval signifies a major breakthrough in the therapy of superbug gonorrhoea, which until now has been staying ahead of antibiotic development.”

Clinical Trial Data and Global Access

According to findings detailed in a major medical journal, zoliflodacin cured the vast majority of uncomplicated infections. This puts it on an similar efficacy with the current standard treatment, which uses an injection and a pill. The research involved over 900 volunteers from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its development partnership, GARDP has the ability to register and commercialise the drug in numerous regions with limited resources.

Clinicians directly involved have voiced positive views. Having a one-pill regimen such as this is seen as a "game-changer" for gonorrhoea control. This is deemed vital to lessen the impact of the infection for people and to prevent the spread of highly drug-resistant gonorrhoea globally.